West Michigan Cancer Center

Clinical Trials & Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

What are Clinical Trials?

Clinical trials bring the latest research to the fight against cancer and blood diseases. The many advances made in the treatment of cancer and blood diseases over the past three decades began as research and clinical trials. As a research volunteer, you play a pivotal role in the pursuit of new and more successful treatments. You will also have access to new procedures and new medications before they are available to the general public.

Clinical trials improve our understanding of how to treat and prevent cancers. Trials are conducted to establish guidelines for the standard of care and to evaluate these treatments in a controlled and safe setting. Clinical trials can help improve the care of cancer patients.

Contact Us
If you have questions about clinical trials, you can reach us by email at research@wmcc.org or by phone at 269.373.7443.

Why Participate in a Clinical Trial?

You may choose to participate in clinical trials for a variety of reasons. Volunteering for research studies can provide access to promising new drugs before they are available to the general public. While there is always a chance that a new treatment will prove to be less effective than hoped, there is also reason to believe that it will be as good or better than current treatments. Every effort is made to ensure your safety; the care from the physicians during the study is highly controlled and monitored.

Here are some helpful links to videos from the National Cancer Institute’s Community Oncology Research Program that may answer your questions:

What Kinds of Trials are Available?

Clinical trials study ways to prevent, detect, diagnose, control, and treat disease. Some trials study the impact that treatment or disease can have on our overall well-being. Studies also look at ways to improve patient comfort and quality of life (including pain management).

Trials that test new modalities may involve surgery, radiation therapy, and chemotherapy. Alone or in combination, these types of treatments can cure many patients and prolong the lives of others.

Clinical trials are currently available through West Michigan Cancer Center Radiation & Surgical Specialties and our affiliated resources.
Please click below for a list of current clinical trials.

This list contains all the current, active, approved protocols for the Cancer Research Consortium of West Michigan—a grant-funded program through the National Cancer Institute Clinical Oncology Research Program (NCORP).

NCORP-approved studies are available through our affiliation with the following research bases: Alliance, ECOG-ACRIN, NRG Oncology and SWOG.

If you would like further information on these or other clinical trials, please call the Cancer Research Consortium of West Michigan at (269) 373-7443. For information regarding pediatric studies, please call (269) 341-6350.

A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngoimas

A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma 

N0577: CODEL: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

NRG-BN007: A Randomized Phase II/III Open-label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Newly Diagnosed Mgmt (Tumor O-6-methylguanine DNA Methyltransferase) Unmethylated Glioblastoma 

A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

EA1181: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

NRG BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

NRG BR007: Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer 

A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patient with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)

A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

BESPOKE Registry: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

EA2176: A Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients 

EA2182: A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial 

NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) 

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors – MALE GENDER ONLY

A031803: Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

EA2183: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

NRG GU002: Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel

NRG GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer

S1823: A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors 

EAY131 (MATCH): Molecular Analysis for Therapy Choice

GOG 0263: Randomized phase III clinical trial of adjuvant radiation vs. chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

NRG-GY018: A Phase III Randomized, Placebo-controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or Iva, Stage Ivb or Recurrent Endometrial Cancer

NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

RTOG 0724: Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy

TAPUR: The Targeted Agent and Profiling Utilization Registry Study

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

RTOG 1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

A041501: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI – 1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

A051701: Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas

Dana Farber 14-174: Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome

EA4181: A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma

S1318: Ph II – Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Pts >/= 65 Yrs w/ Newly Diagnosed Ph- ALL and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Yrs w/ Newly Diagnosed Ph+ ALL

S1608: Randomized Phase II Study in Early Relapsing or Refractory Follicular Lymphoma

S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study 

A081801: Integration of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST CHEMO-IO

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (A Screening Trial for E4512 & EA5142)

A171901: Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)

Calithera CX-839-014: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)

E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (Pts must be registered to the ALCHEMIST Screen (A151216) prior to randomization)

EA5181: Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer 

NRG-LU002: Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

S1827: A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer (MAVERICK)

S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) 

S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

EA6174: STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial

EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

EA6194: Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

S2000: A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab In BRAF-V600 Mutant Melanoma with Brain Metastases 

9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program

EAY131 (MATCH): Molecular Analysis for Therapy Choice

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (For patients that did not have a match to a molecularly guided therapy on EAY131 – MATCH or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations)

TAPUR: The Targeted Agent and Profiling Utilization Registry Study

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Celgene NDS-MM-004: A Multi-Center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPE) for Multiple Myeloma (MM) Digital Care Network in Patients with MM

EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

S0820: Phase III Double Blind Placebo-Controlled Trial of Eflomithine & Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer

WF 1802: Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Our Clinical Trial Partnerships

  • Cancer Research Consortium of West Michigan
  • National Cancer Institute Community Oncology Research Program
  • Dana Farber Cancer Institute
  • Pharmaceutical and Biotech Collaborations

Cancer Research Consortium of West Michigan (CRCWM)

Eleven hospitals and health care systems, including West Michigan Cancer Center Radiation & Surgical Specialties, are part of a consortium called the Cancer Research Consortium of West Michigan (CRCWM). This consortium brings the highest level of clinical trials from the National Cancer Institute (NCI) to the men, women, and children of our communities.

National Cancer Institute Community Oncology Research Program (NCORP)

The NCI supports the consortium as a National Cancer Institute Community Oncology Research Program (NCORP). This collaboration provides new cutting edge clinical cancer trials to patients in our community.

CRCWM members include:

  • West Michigan Cancer Center
  • Bronson Battle Creek
  • Mercy Health Mercy Campus Muskegon
  • Mercy Health Saint Mary's Grand Rapids
  • Metro Health Hospital Wyoming
  • Michigan State University College of Human Medicine Grand Rapids
  • Munson Medical Center Traverse City
  • Spectrum Health Grand Rapids
  • Spectrum Health Lakeland Saint Joseph
  • Spectrum Health Reed City Hospital Reed City
  • Van Andel Research Institute Grand Rapids

More information about the Cancer Research Consortium of West Michigan can be found at www.crcwm.org. Research conducted through the CRCWM NCORP grant is supported by the National Cancer Institute of the National Institutes of Health under Award Number UG1CA189860.

Certain blood cancer patients treated at WMCC can participate in clinical trials offered by the renowned Dana-Farber Cancer Institute due to a collaboration between our centers. WMCC is one of the oncology practices nationwide to join a consortium with Boston-based Dana-Farber, a stand-alone hospital affiliated with Harvard Medical School. The Blood Cancer Research Partnership (BCRP) provides innovative clinical trials to patients closer to their homes.
WMCC has agreements with pharmaceutical and biotech companies that provide trial options for patients in the community.

Trial Safety

Although trials may have different focuses such as prevention, screening, treatment or improving symptoms in patients, all trials follow the same core principles. These three main principles are

Respect for Persons – the participant should be given the information in a format they can understand and given the option to participate or decline the trial voluntarily.

Beneficence – protect the patient by doing more good than harm.

Justice – individuals should have the same opportunity to join a trial regardless of financial, racial, or demographic status.

Safety committees are in place to ensure the well-being of participants in all clinical trials.

Questions to Ask Before Participating

If you are thinking about taking part in a clinical trial, there are some important questions you should ask:

  • What is the purpose of the study?
  • What does the study involve? What kinds of tests and treatments?
  • What is likely to happen in my case with my participation in this study?
  • Are there standard treatments for my case? And if a study is chosen, how do they compare?
  • What other choices do I have? Advantages and disadvantages?
  • How could the study affect my daily life?
  • What side effects could I expect from the study?
  • How long will the study last? Will it require an extra time commitment on my part?
  • Will I have to be hospitalized? If so, for how long?
  • Will I have any expenses? Will any part of the treatment be free?
  • If I were harmed as a result of the research, what treatment would I be entitled to?
  • What type of long-term follow-up care is part of the study?

Research Team

Our team consists of physicians, nurses, regulatory specialists, and clinical research associates.
The research department facilitates the day to day operations of the clinical trials by ensuring the following.

  • Regulatory documents comply with federal guidelines.
  • Data is accurate and timely.
  • Care is given according to the clinical trial guidelines.

IRB (Institutional Review Board)

West Michigan Cancer Center IRB oversees all research studies, and safeguards the rights and welfare of research participants.
As regulated by the United States Department of Health & Human Services, it comprises at least five members of varying backgrounds. The IRB membership includes community members with non-scientific backgrounds, as well as healthcare professionals with the competency to review research. WMCC’s IRB meets every month to review proposals for research studies. Research at WMCC follows regulations and guidelines established by:

  • The U.S. Food and Drug Administration (FDA)
  • The Office for Human Research Protection (OHRP)
  • The International Conference on Harmonisation (ICH)
  • National Institutes of Health (NIH)

We make sure research complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Also called the Privacy Rule, this law controls access to and disclosure of a patient’s confidential health information.